Through a discovery-replication design, our study provides compelling evidence that genetic variants in the ALDH1 family, particularly ALDH1A2 rs16939929 A>G, may serve as promising prognostic biomarkers for prostate cancer. This evidence concerns the gene ALDH1A1 and prostate carcinoma.